In a report released today, Michael Matson from Needham reiterated a Buy rating on Merit Medical Systems (MMSI – Research Report), with a price target of $73.00. The company’s shares closed last Wednesday at $65.10.
According to TipRanks.com, Matson is a 4-star analyst with an average return of 4.5% and a 49.5% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Merit Medical Systems with a $75.20 average price target, implying a 14.0% upside from current levels. In a report issued on April 19, Barrington also maintained a Buy rating on the stock with a $82.00 price target.
The company has a one-year high of $73.85 and a one-year low of $51.66. Currently, Merit Medical Systems has an average volume of 394.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Merit Medical Systems, Inc. engages in the manufacture and market of proprietary disposable medical devices. It operates through Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates advanced non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger and William Padilla in July 1987 and is headquartered in South Jordan, UT.
Read More on MMSI: